The results exhibited that in colorectal adenocarcinoma, endometrial carcinoma and esophagogastric adenocarcinoma, patients with LRP2 mutations had higher MSIsensor score than those without LRP2 mutations (Fig. S1B). This evidence concerns the gene LRP2 and endometrial carcinoma.